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SUMMARY
Many patients with myeloid malignancies are ineligible for conventional allogeneic he-
matopoietic stem cell transplantation （allo-HSCT） with myeloablative conditioning because of 
their age, medical problems, or the lack of a suitable HLA-identical related donor. The outcome 
of 9 patients with myeloid malignancies who underwent allo-HSCT following fludarabine- and 
busulfan- based reduced intensity conditioning （RIC） from unrelated or mismatched related 
donor is herein described. Six patients received bone marrow from an unrelated donor, two re-
ceived a serologically mismatched related allograft, and one received serologically mismatched 
unrelated cord blood. All patients demonstrated successfully engraftment at a median of 15 
days and showed complete donor chimerism of 95% on day 28. One patient developed grade 
3 regimen-related toxicity. Grade II to IV acute graft-versus-host disease （GVHD） and exten-
sive type chronic GVHD developed in 6 and 4 patients, respectively. Of the two patients who 
received the second HSCT, one died of relapse and one died of acute GVHD. The remaining 7 
patients are currently alive in remission. The overall survival at 4 years after allo-HSCT was 
77.8%. These observations suggest that these RIC regimens enable rapid engraftment of stem 
cells from alternative donors with tolerable toxicities in patients who are not eligible for con-
ventional HSCT. 
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Ⅰ．Introduction
 A l l ogene i c  hematopo i e t i c  s t em ce l l 
transplantation （allo-HSCT） has become 
established as one of the curative therapies for 
hematologic malignancies and other hematologic 
or immunologic disorders, especial ly for 
myeloid malignancies due to their graft-versus-
leukemia effect［1］. The best results have been 
obtained in younger recipients who underwent 
allo-HSCT from HLA-identical sibling donors 
because of the increased risk of regimen-related 
toxicities （RRT） that occurs with increasing 
age, and graft-versus host disease （GVHD） 
that depends on HLA disparity. Older patients, 
however, constitute a large group of patients 
with an extremely poor prognosis if treated 
with conventional chemotherapy. Most of these 
patients are ineligible for conventional allo-
HSCT with myeloablative conditioning because 
of age, medical problems other than leukemia, 
or the lack of a suitable HLA-identical related 
donor.
 The development of nonmyeloablative 
or reduced-intensity conditioning （RIC） 
regimens has enabled older or medically infirm 
patients with hematologic malignancies to be 
treated with allo-HSCT［2-6］. These regimens 
rely largely on graft-versus-tumor effects 
rather than high-dose therapy to eliminate 
residual malignant cells. Several studies have 
demonstrated a sustained engraftment with 
a relatively low risk of RRT and non-relapse 
mortality. The most widely applied combinations 
of the RIC regimens consist of fludarabine 
（Flu） plus alkylating agents （busulfan （BU）, 
cyclophosphamide （CY）, or melphalan）［2,3,5］, 
which are chosen for their immunosuppressive 
and anti-neoplastic capacities, respectively, or 
fludarabine plus low-dose total body irradiation 
（TBI）［4,7］.
 Recently, allo-HSCT from an alternative 
donor has been explored for patients who lack a 
suitable HLA-identical sibling donor. It involves 
allo-HSCT from HLA-matched unrelated donor 
（UR-BMT）, HLA-mismatched related donor, or 
cord blood transplantation （CBT）. Some reports 
indicate that the outcomes from alternative 
donors are comparable to that from HLA-
identical siblings using a myeloablative regimen 
［8,9］. However, few data are presently available 
for allo-HSCT from alternative donors with RIC 
regimens for elderly or infirm patients. 
 This study reports the outcome of 9 patients 
with myeloid malignancies who underwent 
either unrelated or mismatched related donor 
allo-HSCT following a Flu and BU-based RIC 
regimen between July 2003 and May 2007.
Ⅱ．Patients and Methods
Patient Characteristics
 Between July 2003 and May 2007, 9 patients 
with myeloid malignancies underwent allogeneic 
HSCT with a Flu and BU-based RIC regimen. 
Transplantation candidates with RIC regimen 
were required to have at least one of the 
following risk factors: （1） an age older than 55 
years, （2） comorbidity, and （3） treatment failure 
after intensive therapies including allo-HSCT 
with a myeloablative conditioning regimen. The 
characteristics of the patients at the time of 
transplantation are summarized in Table 1. The 
median age of the patients was 55 years （range, 
45 to 60 years） with a sex ratio （M/F） of 6/3. 
The follow-up period ranged from 106 to 1626 
days （median, 758 days）. Six patients received 
bone marrow from an unrelated donor, 1 patient 
received unrelated cord blood, and 2 patients 
received an allograft from a mismatched 
related donor （bone marrow in one patient 
and peripheral blood stem cells in the other）. 
Two patients received the second HSCT with 
RIC regimen. At the time of transplantation, 
3 patients with acute myelogenous leukemia 
（AML） and 2 with myelodysplastic syndrome 
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（MDS） were in complete remission （CR）. One 
patient with chronic myelogenous leukemia 
（CML） was in first chronic phase （CP）. Of the 
remaining 3 patients, two had refractory MDS, 
and one had CML in an accelerated phase （AP）. 
Both patients with CML were refractory to 
imatinib.
HLA compatibility
 Donor-recipient pairs were selected on the 
basis of serologic matching for HLA-A, B, and 
DR antigens. A search for unrelated donors 
was made through the Japan Marrow Donor 
Program （JMDP） for patients without suitable 
HLA-matched related donors. If no appropriate 
related or unrelated donor was identified, 
then the Japanese Cord Blood Bank Network 
（JCBBN） was searched. A cord blood graft was 
selected on the basis of serologic matching for 
4 to 6 antigens at HLA-A, B, and DR loci with 
a total cell dose of greater than 2x107/kg. For 
DRB1 and some A and B loci, high-resolution 
allele-specific DNA typing was performed. 
Six patients had an unrelated donor selected 
through the JMDP, 3 donor-recipient pairs 
of them had an allele-level single mismatch 
（HLA-A locus, two pairs; DRB1 locus, one pair）. 
One patient had an unrelated donor selected 
through the JCBBN, which was mismatched 
for two antigens （HLA-A and B loci）. The 
remaining two patients had a related donor; 
one patient received a single antigen （HLA-B 
locus） mismatched bone marrow and the other 
received two antigens （HLA-B and DR loci） 
mismatched peripheral blood stem cells.
Conditioning regimens
 The conditioning regimen consisted of 30 
mg/m2 Flu intravenously daily from days -7 to 
day -2 （total dose 180 mg/m2）, 4 mg/kg BU 
Table 1　Patient characteristics
Patient Age at Sex Diagnosis Disease status at Prior Cytogenetics RIC risk factors Time from Dx
No. transplantation transplantation treatments to HSCT（month）
1 46 F CML first CP imatinib t（9;22） imanitib resistance, 19.3
ovary cancer
2 60 M AML（M3） fourth CR chemotherapy, t（15;17） advanced disease, 74.3
retinoic acid age
3 55 M AML（M1） first CR chemotherapy complex primary refractory, 6.4
age
4 56 M AML（M4） third CR chemotherapy inv（16） advanced disease, 21.0
age
5 56 M MDS（RAEB） first CR chemotherapy complex colon cancer, 8.7
age
6 56 M MDS overt leukemia on disease chemotherapy normal primary refractory, 3.4
infection, age
7 45 M CML AP imatinib t（9;22） imatinib resistance, 33.3
myocardial infarction
8 47 F MDS overt leukemia second CR chemotherapy, （not done） primary refractory 35.8
R-PBSCT（CY/TBI） 2nd HSCT
9 50 F Secondary MDS（RAEB） on disease chemotherapy, 8 trisomy primary refractory 6.5
R-BMT（CY/TBI） 2nd HSCT
RAEB, refractory anemia with excess of blast; CR, complete remission; CP, chronic phase; AP, accelerated phase; R, related; PBSCT, peripheral 
blood stem cell transplantation; CY/TBI, cyclophosphamide and total body irradiation; Dx, diagnosis
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orally daily on days -5 and -4 （total dose 8 mg/
kg）, and 4 Gy TBI on day -1 （single dose or 2 
divided doses）. Two patients （Nos. 8 and 9）, 
who had undergone their first allo-HSCT with a 
TBI-containing myeloablative regimen, received 
the following non-TBI regimen, respectively: （1） 
30 mg/m2 Flu intravenously daily from days -8 
to day -4 （total dose 150 mg/m2） and 4 mg/kg 
BU orally daily on days -5 and -4 （total dose 8 
mg/kg）, （2） 30 mg/m2 Flu intravenously daily 
from day -7 to day -2 （total dose 180 mg/m2）, 
4 mg/kg BU orally daily on days -5 and -4 
（total dose 8 mg/kg）, and 80 mg/m2 melphalan 
intravenously on day -2.
Prophylaxis and treatment of GVHD
 The patients received a combination of 
cyclosporine A （CsA） and short course of 
methotrexate （MTX） as prophylaxis for GVHD. 
MTX was administered intravenously at a dose 
of 10 mg/m2 on day 1 and a dose of 7 mg/m2 on 
days 3 and 6. CsA was administered at a dose 
of 3 mg/kg/day from day -1 as a continuous 
intravenous infusion adjusted to maintain a 
trough level of 350 to 400 ng/ml. Two patients 
received a combination of tacrolimus and the 
same dose and schedule of MTX because of 
an allograft from a serologically single antigen 
mismatched related donor or an allele-level 
single mismatched unrelated donor. Tacrolimus 
was administered at a dose of 0.025 mg/kg/day 
from day -1 as a continuous intravenous infusion 
adjusted to maintain a trough level of 15 to 20 
ng/ml. One patient （No. 8） who underwent 
the second HSCT from the same donor in a 
previous allo-HSCT, received CsA alone. The 
intravenous administration of CsA or tacrolimus 
was substituted by the oral administration 
when tolerated. CsA or tacrolimus was tapered 
5% per week after day 50 if the patient had 
no GVHD. Acute and chronic GVHD were 
diagnosed and graded according to the 
established criteria［10,11］. Chronic GVHD was 
evaluated in patients who had survived at least 
100 days with sustained engraftment. Acute 
GVHD was treated primarily with 1-2 mg/kg of 
prednisolone （PSL）. Extensive chronic GVHD 
was treated primarily with PSL and CsA/
tacrolimus.
Engraftment, a chimerism analysis and survival
 The day on which granulocyte engraftment 
was achieved was defined as the first of 3 
consecutive days on which the patient achieved 
a granulocyte count of greater than 0.5 x 
109/L. The day on which platelet engraftment 
was achieved was defined as the first of 7 
consecutive days with a platelet count of 
greater than 50 x 109/L without platelet 
infusion. A chimerism analysis was performed 
on the bone marrow at four weeks interval by 
variable number of tandem repeat （VNTR） 
single nucleotide polymorphism analysis using 
the polymerase chain reaction. The disease-free 
survival （DFS） and overall survival （OS） of the 
patients after allo-HSCT was analyzed by the 
Kaplan-Meier method.
Supportive Care
 Ant im icrob ia l  prophy lax i s  inc luded 
levofloxacin for bacterial infection, fluconazole 
f o r  f u n g a l  i n f e c t i o n ,  t r i m e t h o p r i m /
sulfamethoxazole for Pneumocystis carinii 
infection, and acyclovir for Herpes virus 
infection according to the institutional protocol. 
Monitoring for cytomegalovirus （CMV） 
antigenemia was performed once a week after 
the engraftment, with ganciclovir therapy 
started if positive results were obtained.
Ⅲ．Results
Engraftment and Chimerism analysis
 The clinical outcomes for all patients 
are summarized in Table 2. All patients 
d emons t r a t ed  a  s u c c e s s f u l  s u s t a i n ed 
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engraftment. Granulocyte engraftment was 
achieved at a median of 15 days （range, 14 to 22 
days）, and platelet engraftment was achieved at 
a median of 25 days （range, 13 to 35 days） after 
the HSCT. A chimerism analysis confirmed 
more than 95% donor-type engraftment by 
day 28 in all patients. In addition, no patient 
developed either primary or secondary graft 
failure.
Acute and chronic GVHD
 Five patients developed grade II to III acute 
GVHD （related marrow transplantation, n＝
1; unrelated marrow transplantation, n＝4）. 
One patient （No. 9） who underwent the second 
HSCT for secondary MDS after the previous 
allo-HSCT developed grade IV acute GVHD. 
All patients survived at least 100 days after the 
HSCT. Among them, five patients developed 
chronic GVHD （one patient with limited and 
four patients with extensive GVHD）. The 
affected organs included the skin （n＝4）, mouth 
（n＝3）, liver （n＝2）, and eye （n＝1）.
Regimen-related Toxicities and Infections
 RRT was defined as any non-hematologic 
organ dysfunction from day 0 to day 28 
according to Bearman et al.’s criteria［12］. 
Table 2　Transplantation characteristics
Patient Stem cell HLA disparity RIC regimen GVHD Granulocyte Platelet Chimerism（VNTR） 
No. source Serology DNA typing prophylaxis ＞500/μL ＞20000/μL Donor %
（day） （day）
1 UR-BMT identical A Flu+BU+TBI CsA+sMTX 15 20 95%
2 UR-BMT identical DRB1 Flu+BU+TBI CsA+sMTX 14 32 100%
3 R-BMT B B Flu+BU+TBI FK506+sMTX 15 17 100%
4 UR-BMT identical full matched Flu+BU+TBI CsA+sMTX 20 20 100%
5 UR-BMT identical full matched Flu+BU+TBI CsA+sMTX 14 25 100%
6 UR-CBT A, B A, B Flu+BU+TBI CsA+sMTX 17 27 100%
7 UR-BMT identical A Flu+BU+TBI FK506+sMTX 22 35 100%
8 R-PBSCT B, DR ND Flu+BU CsA 14 13 100%
9 UR-BMT identical full matched Flu+BU+Mel CsA+sMTX 18 28 100%
Table 3　Transplantation outcomes
Patient Acute GVHD Chronic GVHD Regimen-related Documented infection within Survival Current status
No. Grade Skin Gut Liver （involved organs） toxicity 100 days（causative pathogen）（days）（cause of death）
1 II 3 0 0 extensive（liver, mouth） none none 1626 alive in CR
2 II 3 0 1 extensive（skin, eye, mouth） none none 1514 alive in CR
3 II 3 1 0 extensive（skin, mouth） liver and kidney injury enterocolitis（C. difficile） 1216 alive in CR
4 II 3 0 0 extensive（skin, liver） none none 807 alive in CR
5 I 2 0 0 limited（skin） hemorrhagic cystitis none 758 alive in CR
6 0 0 0 0 （-） none pneumonia（CMV, HHV8） 508 alive in CR
7 III 0 4 0 （-） none enterocolitis（C. difficile） 311 alive in CR
CMV antigenemia
8 0 0 0 0 （-） none none 211 dead（relapse）
9 IV 3 4 0 （not evaluable） TMA CMV antigenemia 106 dead in CR
（acute GVHD）
TMA, thrombotic microangiopathy; CMV, cytomegalovirus; HHV, human herpes virus; C, Clostridium.
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The RIC regimens were well tolerated, and 
the degree of toxicity was mild. Hemorrhagic 
cystitis by Adenovirus type 11 was observed 
in one patient. One patient （No. 9） developed 
grade 3 thrombotic microangiopathy （TMA）
［13］. CMV antigenemia was detected in 3 
patients, of whom one patient developed CMV 
pneumonia which was successfully treated with 
ganciclovir. Enterocolitis due to Clostridium 
difficile developed in two patients. 
Relapse, non-relapse mortality and survival
 One pat ient  （No.  8） wi th MDS who 
underwent the second HSCT from the same 
donor in previous allo-HSCT relapsed on day 
125 and died. One patient （No. 9） died of acute 
GVHD on day 106. As of December 2007, all 
other seven patients are alive in CR with full 
donor chimerism at a median follow-up of 807 
days （range, 124 to 1626 days）. Both the DFS 
and OS of the patients at 4 years after allo-
HSCT were 77.8% （Fig. 1）.
Ⅳ．Discussion
 Graft failure and non-relapse mortality are 
major problems after allo-HSCT with an RIC 
regimen, especially for transplantation from 
unrelated or mismatched related donors［14］. 
In the present series, rapid and sustained 
engraftment with complete donor chimerism 
was demonstrated in all patients, including 
one patient who received unrelated cord blood 
mismatched at 2 HLA-antigens. Previous 
heavy treatment and a relatively intensive 
RIC regimen may contribute, in part, to 
successful engraftment. The low RRT using 
this RIC regimens is also remarkable. Only one 
patient developed grade 3 TMA. This patient 
developed TMA concomitant with acute GVHD 
after achieving complete donor chimerism, 
thus suggesting that TMA was primarily 
due to acute GVHD rather than RRT from 
the conditioning treatment. No veno-occlusive 
disease was observed.
 Relapse and progressive disease continues 
to be the major cause of treatment failure after 
the RIC regimen, particularly in patients with 
large tumor burdens at time of transplantation
［6,15,16］. Refractory or rapidly progressing 
disease （i.e., high-risk AML or MDS） may be 
best-controlled using a conditioning regimen 
with a greater anti-neoplastic intensity［7］. 
Previous studies have demonstrated that allo-
HSCT with RIC regimen can benefit patients 
with high-risk AML or MDS［15-17］. Despite the 
fact that the patients in this study were mostly 
high-risk; two underwent a second HSCT, three 
had adverse cytogenetics, two were in beyond 
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Fig. 1　 Survival of the patients after allo-HSCT 
with the RIC regimen. 
　（A） Disease-free survival （DFS）, （B） Overall 
survival （OS）. Both DFS and OS at 4 years post 
transplantation are 77.8%. 
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second CR or non-remission; only one patient 
with refractory MDS （No. 8） relapsed. Because 
this patient had many anti-HLA antibodies and 
no HLA-matched related or unrelated donor, 
she underwent a second HSCT with RIC from 
the same donor （2-HLA-antigen mismatched 
daughter） of the initial myeloablative HSCT 
in complete donor chimerism. She did not 
experience either acute or chronic GVHD and 
relapsed on day 125.
 Baron et al. demonstrated in their analysis 
o f  HLA-matched  re l a t ed  o r  unre l a t ed 
nonmyeloablative HSCT that chronic extensive 
GVHD was highly associated with a decreased 
risk of relapse/progression and significantly 
better progression-free survival［18］.  On 
the other hand, grade II to IV acute GVHD 
was not associated with decreased risk of 
relapse but, rather, caused increased non-
relapse mortality and therefore, significantly 
decreased progression-free survival［18］. In the 
current series, six out of 9 patients developed 
grade II to IV acute GVHD, which mainly 
manifested as skin rashes. One patient （No. 7） 
who received one allele-mismatched unrelated 
BMT developed grade III acute GVHD which 
manifested as gastrointestinal symptoms and 
Clostridium difficile enterocolitis simultaneously. 
One patient （No. 9）, who underwent the second 
HSCT with RIC for secondary MDS after the 
initial myeloablative HSCT, developed severe 
acute GVHD. Although TMA was successfully 
managed by plasma exchange, she progressed 
to grade IV acute GVHD and eventually died 
from multi-organ failure on day 106. Five out of 
9 patients developed chronic GVHD, of whom 
four had extensive disease. These patients were 
all successfully managed and did not show a 
fatal outcome. 
 Except for 2 pat ients with a second 
transplantation, seven patients with their first 
transplantation are currently alive in remission. 
This result is very promising for patients with 
myeloid malignancies who could not receive 
myeloablative conditioning because of higher 
age or medical problems and lack of family 
donor. Despite the small number of patients and 
the short follow-up period, these observations 
suggest that Flu and BU-based RIC regimens 
reduce the risk of graft failure and enable rapid 
engraftment of complete donor chimerism with 
tolerable RRT even in unrelated or mismatched 
related donor HSCT setting. However, these 
regimens might be inappropriate and not 
widely applicable for the second HSCT. Further 
investigations are thus called for.
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要　　旨
　同種造血幹細胞移植療法の最近の進歩は著しいが，
高齢や臓器障害，合併症などの理由により，通常の骨
髄破壊的前処置による同種造血幹細胞移植の適応にな
らない患者は未だ多く，さらにHLA適合血縁ドナーを
有する患者は30％以下に限られる。我々は，HLA適合
血縁ドナーを有しない骨髄系悪性腫瘍 9症例に対して，
フルダラビンとブスルファンを基本とする用量減量前
処置により，非血縁者間またはHLA不適合血縁者間
同種造血幹細胞移植を行った。血縁者間骨髄移植が 6
例，HLA血清型不適合血縁者間移植が 2例，HLA血清
型不適合非血縁者間臍帯血移植が 1例。全例で移植後
中央値15日目に生着が得られ，28日目にはドナー型が
95%以上の完全キメラとなった。 1例でグレード 3の
移植関連毒性がみられた。 2度以上の急性GVHDを 6
例に認め，全身型の慢性GVHDを 4例に認めた。移植
後100日以内の早期死亡はなく， 2回目の造血幹細胞移
植であった 2症例のうち， 1例が再発にて， 1例が急
性GVHDにて死亡した。残る 7症例は現在も寛解生存
中であり，同種造血幹細胞移植後の 4年無病生存率は
77.8%であった。これらの結果から，通常の骨髄破壊的
移植が適応にならず，HLA適合血縁ドナーを有しない
症例に対しても，今回の用量減量前処置を用いた同種
移植によりドナー幹細胞の速やかな生着が得られ，毒
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性が軽度で比較的安全に施行できることが示され，移
植適応のさらなる拡大が期待できることが示唆された。
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